INTRODUCTION: Neoadjuvant chemotherapy (NAC) prior to radical or partial cystectomy is considered the standard of care for eligible patients with muscle-invasive urothelial carcinoma. Despite guideline recommendations, adoption of NAC has historically been low, although prior studies have suggested that use is increasing. In this contemporary study, we examine trends in the use of NAC and explore factors associated with its receipt. METHODS: We identified patients in the National Cancer Database who underwent radical or partial cystectomy for cT2-cT4N0M0 urothelial carcinoma from 2006-2014. The proportion of patients receiving NAC during each year was examined. Logistic regression models were used to evaluate clinical and socioeconomic factors associated with the receipt of NAC. RESULTS: A total of 18 188 patients were identified who underwent radical or partial cystectomy for muscle-invasive bladder cancer. Overall, 3940 (21.7%) received NAC. We noted a significant increase in the use of NAC over time, from 9.7% in 2006 to 32.2% in 2014. Factors associated with lower use of NAC include older age, higher comorbidity score, lower cT stage, lower hospital radical cystectomy volume, treatment at a non-academic facility, lower patient income, and receipt of partial cystectomy (all p<0.001). Interestingly, neither sex nor race were associated with receipt of NAC. CONCLUSIONS: Use of NAC has increased significantly over time to a modest rate of 32%. However, disparities still exist in the receipt of NAC, and future efforts aimed at mitigating these disparities are warranted.
INTRODUCTION: Neoadjuvant chemotherapy (NAC) prior to radical or partial cystectomy is considered the standard of care for eligible patients with muscle-invasive urothelial carcinoma. Despite guideline recommendations, adoption of NAC has historically been low, although prior studies have suggested that use is increasing. In this contemporary study, we examine trends in the use of NAC and explore factors associated with its receipt. METHODS: We identified patients in the National Cancer Database who underwent radical or partial cystectomy for cT2-cT4N0M0 urothelial carcinoma from 2006-2014. The proportion of patients receiving NAC during each year was examined. Logistic regression models were used to evaluate clinical and socioeconomic factors associated with the receipt of NAC. RESULTS: A total of 18 188 patients were identified who underwent radical or partial cystectomy for muscle-invasive bladder cancer. Overall, 3940 (21.7%) received NAC. We noted a significant increase in the use of NAC over time, from 9.7% in 2006 to 32.2% in 2014. Factors associated with lower use of NAC include older age, higher comorbidity score, lower cT stage, lower hospital radical cystectomy volume, treatment at a non-academic facility, lower patient income, and receipt of partial cystectomy (all p<0.001). Interestingly, neither sex nor race were associated with receipt of NAC. CONCLUSIONS: Use of NAC has increased significantly over time to a modest rate of 32%. However, disparities still exist in the receipt of NAC, and future efforts aimed at mitigating these disparities are warranted.
Authors: Shabnam Rehman; Alice Crane; Rakeeba Din; Syed Johar Raza; Yi Shi; Gregory Wilding; Ellis G Levine; Saby George; Roberto Pili; Donald L Trump; Khurshid A Guru Journal: Urology Date: 2013-10-11 Impact factor: 2.649
Authors: Marc C Smaldone; Jay Simhan; Alexander Kutikov; Daniel J Canter; Russell Starkey; Fang Zhu; Matthew E Nielsen; Karyn B Stitzenberg; Richard E Greenberg; Robert G Uzzo Journal: Urol Oncol Date: 2012-06-09 Impact factor: 3.498
Authors: Brendan J W Miles; Adrian S Fairey; Michael Eliasziw; Eric P Estey; Peter Venner; Daygen Finch; Kiril Trpkov; Bernhard J Eigl Journal: Can Urol Assoc J Date: 2010-08 Impact factor: 1.862
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Stephen H Culp; Rian J Dickstein; H Barton Grossman; Shanna M Pretzsch; Sima Porten; Siamak Daneshmand; Jie Cai; Susan Groshen; Arlene Siefker-Radtke; Randall E Millikan; Bogdan Czerniak; Neema Navai; Matthew F Wszolek; Ashish M Kamat; Colin P N Dinney Journal: J Urol Date: 2013-07-30 Impact factor: 7.450
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Kristen E Rhodin; Anthony W Kim; Betty C Tong; Thomas A D'Amico; David H Harpole Journal: Ann Thorac Surg Date: 2020-07-03 Impact factor: 4.330
Authors: Juan J Andino; Michael Sessine; Udit Singhal; Zachery R Reichert; Daniel Wray; Christine Shafer; Marissa Moore; Alon Z Weizer; Samuel D Kaffenberger; Lindsey A Herrel; Todd M Morgan; Khaled Z Hafez; Jeffrey S Montgomery Journal: Urol Pract Date: 2020-10-14
Authors: Anirban P Mitra; Jie Cai; Gus Miranda; Sumeet Bhanvadia; David I Quinn; Anne K Schuckman; Hooman Djaladat; Siamak Daneshmand Journal: J Urol Date: 2021-11-08 Impact factor: 7.450
Authors: N Beije; I E de Kruijff; J J de Jong; S O Klaver; P de Vries; R A L Jacobs; D M Somford; E Te Slaa; A G van der Heijden; J Alfred Witjes; L M C L Fossion; E R Boevé; J van der Hoeven; H H E van Melick; C J Wijburg; H Bickerstaffe; J W M Martens; R de Wit; J Kraan; S Sleijfer; J L Boormans Journal: ESMO Open Date: 2022-03-03